HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test

A new genotyping-based DNA assay (Digene LQ(®)) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Halfon, Philippe, Lindemann, Maria Luisa Mateos, Raimondo, Audrey, Ravet, Sophie, Camus, Claire, Khiri, Hacène, Pénaranda, Guillaume, Sideri, Mario, Sandri, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668127/
https://www.ncbi.nlm.nih.gov/pubmed/23299934
http://dx.doi.org/10.1007/s00705-012-1584-4
_version_ 1782271572900315136
author Halfon, Philippe
Lindemann, Maria Luisa Mateos
Raimondo, Audrey
Ravet, Sophie
Camus, Claire
Khiri, Hacène
Pénaranda, Guillaume
Sideri, Mario
Sandri, Maria Teresa
author_facet Halfon, Philippe
Lindemann, Maria Luisa Mateos
Raimondo, Audrey
Ravet, Sophie
Camus, Claire
Khiri, Hacène
Pénaranda, Guillaume
Sideri, Mario
Sandri, Maria Teresa
author_sort Halfon, Philippe
collection PubMed
description A new genotyping-based DNA assay (Digene LQ(®)) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease. The study population comprised 376 ASCUS women. The women were all Hybrid Capture II (HCII) positive and were admitted in three European referral gynecology clinics between 2007 and 2010. A colposcopy with histological examination was performed in all these patients. HPV 16 was typed in 40 % of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and 18 % of patients had mixed genotypes. Patients aged over 30 more often had the HPV 16 genotype than patients aged under 30 (29 % vs. 11 %, chi-square test p < 0.001). The risk of cervical intra-epithelial neoplasia of grade 2 or more (CIN2 +) when HPV 18 positive is lower than the probability associated with HPV 16 or HPV 31: 28 % vs. 58 % and 52 %, respectively (chi-square test, p = 0.005 and p = 0.05, respectively). The Digene LQ(®), a new sequence-specific hybrid capture sample preparation, is fast and efficient and allows high-throughput genotyping of 18 HR HPV types by PCR compared to traditional non-sequence-specific sample preparation methods.
format Online
Article
Text
id pubmed-3668127
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-36681272013-06-03 HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test Halfon, Philippe Lindemann, Maria Luisa Mateos Raimondo, Audrey Ravet, Sophie Camus, Claire Khiri, Hacène Pénaranda, Guillaume Sideri, Mario Sandri, Maria Teresa Arch Virol Original Article A new genotyping-based DNA assay (Digene LQ(®)) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease. The study population comprised 376 ASCUS women. The women were all Hybrid Capture II (HCII) positive and were admitted in three European referral gynecology clinics between 2007 and 2010. A colposcopy with histological examination was performed in all these patients. HPV 16 was typed in 40 % of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and 18 % of patients had mixed genotypes. Patients aged over 30 more often had the HPV 16 genotype than patients aged under 30 (29 % vs. 11 %, chi-square test p < 0.001). The risk of cervical intra-epithelial neoplasia of grade 2 or more (CIN2 +) when HPV 18 positive is lower than the probability associated with HPV 16 or HPV 31: 28 % vs. 58 % and 52 %, respectively (chi-square test, p = 0.005 and p = 0.05, respectively). The Digene LQ(®), a new sequence-specific hybrid capture sample preparation, is fast and efficient and allows high-throughput genotyping of 18 HR HPV types by PCR compared to traditional non-sequence-specific sample preparation methods. Springer Vienna 2013-01-09 2013 /pmc/articles/PMC3668127/ /pubmed/23299934 http://dx.doi.org/10.1007/s00705-012-1584-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Halfon, Philippe
Lindemann, Maria Luisa Mateos
Raimondo, Audrey
Ravet, Sophie
Camus, Claire
Khiri, Hacène
Pénaranda, Guillaume
Sideri, Mario
Sandri, Maria Teresa
HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title_full HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title_fullStr HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title_full_unstemmed HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title_short HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
title_sort hpv genotype distribution according to severity of cervical neoplasia using the digene hpv genotyping lq test
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668127/
https://www.ncbi.nlm.nih.gov/pubmed/23299934
http://dx.doi.org/10.1007/s00705-012-1584-4
work_keys_str_mv AT halfonphilippe hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT lindemannmarialuisamateos hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT raimondoaudrey hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT ravetsophie hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT camusclaire hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT khirihacene hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT penarandaguillaume hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT siderimario hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest
AT sandrimariateresa hpvgenotypedistributionaccordingtoseverityofcervicalneoplasiausingthedigenehpvgenotypinglqtest